Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells $1,128,600.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at $41,403,763.17. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Helen Torley also recently made the following trade(s):

• On Tuesday, June 24th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $53.73, for a total value of $1,074,600.00.
• On Friday, June 20th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $52.96, for a total value of $1,059,200.00.

Halozyme Therapeutics Price Performance

Shares of HALO traded down $0.48 on Friday, hitting $57.15. The company's stock had a trading volume of 1,242,806 shares, compared to its average volume of 1,758,707. The company has a market capitalization of $7.04 billion, a PE ratio of 15.20, a PEG ratio of 0.38 and a beta of 1.15. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.51. The company has a 50 day moving average price of $55.03 and a 200 day moving average price of $57.01.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The business had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same period in the previous year, the business earned $0.79 EPS. Halozyme Therapeutics's revenue was up 35.2% compared to the same quarter last year. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Finally, Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $62.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HALO. Norges Bank acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $60,054,000. Capital World Investors acquired a new stake in Halozyme Therapeutics during the 4th quarter worth $35,773,000. Arrowstreet Capital Limited Partnership raised its stake in Halozyme Therapeutics by 141.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock worth $47,470,000 after buying an additional 581,475 shares during the period. Caisse DE Depot ET Placement DU Quebec raised its stake in Halozyme Therapeutics by 154.5% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 910,169 shares of the biopharmaceutical company's stock worth $58,078,000 after buying an additional 552,590 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its stake in Halozyme Therapeutics by 171.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after buying an additional 524,802 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.